ATE527243T1 - Calciumkanal-antagonisten vom typ chinazolinon t - Google Patents
Calciumkanal-antagonisten vom typ chinazolinon tInfo
- Publication number
- ATE527243T1 ATE527243T1 AT06737357T AT06737357T ATE527243T1 AT E527243 T1 ATE527243 T1 AT E527243T1 AT 06737357 T AT06737357 T AT 06737357T AT 06737357 T AT06737357 T AT 06737357T AT E527243 T1 ATE527243 T1 AT E527243T1
- Authority
- AT
- Austria
- Prior art keywords
- quinazolinone
- type
- calcium channel
- channel antagonists
- compounds
- Prior art date
Links
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title abstract 2
- 229940127291 Calcium channel antagonist Drugs 0.000 title 1
- 102000003691 T-Type Calcium Channels Human genes 0.000 abstract 3
- 108090000030 T-Type Calcium Channels Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- C07D239/82—Oxygen atoms with an aryl radical attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65995405P | 2005-03-09 | 2005-03-09 | |
| PCT/US2006/008177 WO2006098969A2 (en) | 2005-03-09 | 2006-03-08 | Quinazolinone t-type calcium channel antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE527243T1 true ATE527243T1 (de) | 2011-10-15 |
Family
ID=36992208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06737357T ATE527243T1 (de) | 2005-03-09 | 2006-03-08 | Calciumkanal-antagonisten vom typ chinazolinon t |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7745452B2 (de) |
| EP (1) | EP1858520B1 (de) |
| JP (1) | JP2008533020A (de) |
| KR (1) | KR20070110081A (de) |
| CN (1) | CN101137380A (de) |
| AT (1) | ATE527243T1 (de) |
| AU (1) | AU2006223469A1 (de) |
| BR (1) | BRPI0608343A2 (de) |
| CA (1) | CA2600868A1 (de) |
| IL (1) | IL185391A0 (de) |
| MX (1) | MX2007010965A (de) |
| NO (1) | NO20075074L (de) |
| RU (1) | RU2007137266A (de) |
| WO (1) | WO2006098969A2 (de) |
| ZA (1) | ZA200706740B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006098969A2 (en) * | 2005-03-09 | 2006-09-21 | Merck & Co., Inc. | Quinazolinone t-type calcium channel antagonists |
| WO2008138126A1 (en) * | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
| AU2008275674A1 (en) * | 2007-07-10 | 2009-01-15 | Merck & Co., Inc. | Quinazolinone T-type calcium channel antagonists |
| US8273749B2 (en) | 2007-10-04 | 2012-09-25 | Merck Sharp & Dohme Corp. | N-substituted oxindoline derivatives as calcium channel blockers |
| WO2009044788A1 (ja) * | 2007-10-05 | 2009-04-09 | Banyu Pharmaceutical Co., Ltd. | ベンゾオキサジノン誘導体 |
| JP5718233B2 (ja) | 2008-10-20 | 2015-05-13 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 甲状腺刺激ホルモン受容体（ｔｓｈｒ）の低分子量アゴニスト |
| FR2937552B1 (fr) * | 2008-10-27 | 2011-05-06 | Biocodex | Composition pharmaceutique destinee a la prevention ou au traitement du syndrome de sevrage alcoolique |
| JP5965387B2 (ja) | 2010-04-08 | 2016-08-03 | アメリカ合衆国 | Ｔｓｈ受容体用のインバースアゴニストおよびニュートラルアンタゴニスト |
| WO2011148956A1 (ja) | 2010-05-24 | 2011-12-01 | トーアエイヨー株式会社 | 縮合イミダゾール誘導体 |
| MX362855B (es) * | 2012-09-26 | 2019-02-20 | Merck Patent Gmbh | Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp). |
| IN2014CH00304A (de) * | 2014-01-24 | 2015-09-04 | Discovery Intermediates Pvt Ltd | |
| US9145388B2 (en) | 2014-02-19 | 2015-09-29 | King Fahd University Of Petroleum And Minerals | 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones |
| US9856250B2 (en) | 2014-05-28 | 2018-01-02 | Toa Eiyo Ltd. | Substituted tropane derivatives |
| EP3364993B1 (de) | 2015-10-22 | 2022-11-09 | Cavion, Inc. | Verfahren zur behandlung des angelman-syndroms |
| CN110545806A (zh) | 2017-02-15 | 2019-12-06 | 卡维昂公司 | 钙通道抑制剂 |
| CN106749045B (zh) * | 2017-03-03 | 2020-02-14 | 上海交通大学 | 一种d-氨基酸氧化酶抑制剂及其制法和应用 |
| EP3615521A4 (de) * | 2017-04-26 | 2021-02-17 | Cavion, Inc. | Verfahren zur verbesserung des gedächtnisses und der kognition und zur behandlung von gedächtnis- und kognitiven störungen |
| JP7480131B2 (ja) | 2018-10-03 | 2024-05-09 | カビオン・インコーポレイテッド | （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置 |
| WO2021007487A1 (en) | 2019-07-11 | 2021-01-14 | Praxis Precision Medicines, Inc. | Formulations of t-type calcium channel modulators and methods of use thereof |
| CN118434722A (zh) | 2021-10-20 | 2024-08-02 | 英矽智能科技知识产权有限公司 | 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途 |
| WO2025255502A1 (en) | 2024-06-07 | 2025-12-11 | Cavion, Inc. | PYRIDYL AMIDE Cav3 CHANNEL MODULATORS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993004047A1 (en) * | 1991-08-16 | 1993-03-04 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| IL102764A0 (en) | 1991-08-16 | 1993-01-31 | Merck & Co Inc | Quinazoline derivatives,and pharmaceutical compositions containing them |
| DE4320347A1 (de) * | 1993-06-19 | 1994-12-22 | Boehringer Mannheim Gmbh | Quinazolin-Derivate und diese enthaltende Arzneimittel |
| EP1066039A4 (de) * | 1998-03-02 | 2003-02-26 | Cocensys Inc | Substituierte quinazoline und deren analoge und verwendungen |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| JP3691341B2 (ja) * | 2000-05-16 | 2005-09-07 | 日新製鋼株式会社 | 精密打抜き性に優れたオーステナイト系ステンレス鋼板 |
| AU2003277418A1 (en) * | 2002-10-17 | 2004-05-04 | Merck And Co., Inc. | Enhancement of sleep with t-type calcium channel antagonists |
| EP1667685B1 (de) * | 2003-09-23 | 2012-03-14 | Merck Sharp & Dohme Corp. | Chinazolin-kaliumkanalhemmer |
| US20070010537A1 (en) * | 2004-08-20 | 2007-01-11 | Kazumasa Hamamura | Fused pyramidine derivative and use thereof |
| WO2006098969A2 (en) * | 2005-03-09 | 2006-09-21 | Merck & Co., Inc. | Quinazolinone t-type calcium channel antagonists |
| CA2573525A1 (en) * | 2006-01-12 | 2007-07-12 | Hitachi, Ltd. | Materials location system and selecting method of materials receiving locations |
-
2006
- 2006-03-08 WO PCT/US2006/008177 patent/WO2006098969A2/en not_active Ceased
- 2006-03-08 US US11/886,053 patent/US7745452B2/en not_active Expired - Lifetime
- 2006-03-08 CN CNA2006800072450A patent/CN101137380A/zh active Pending
- 2006-03-08 RU RU2007137266/04A patent/RU2007137266A/ru not_active Application Discontinuation
- 2006-03-08 EP EP06737357A patent/EP1858520B1/de not_active Expired - Lifetime
- 2006-03-08 BR BRPI0608343A patent/BRPI0608343A2/pt not_active IP Right Cessation
- 2006-03-08 AU AU2006223469A patent/AU2006223469A1/en not_active Abandoned
- 2006-03-08 AT AT06737357T patent/ATE527243T1/de not_active IP Right Cessation
- 2006-03-08 JP JP2008500859A patent/JP2008533020A/ja not_active Withdrawn
- 2006-03-08 KR KR1020077020586A patent/KR20070110081A/ko not_active Withdrawn
- 2006-03-08 MX MX2007010965A patent/MX2007010965A/es unknown
- 2006-03-08 CA CA002600868A patent/CA2600868A1/en not_active Abandoned
-
2007
- 2007-08-14 ZA ZA200706740A patent/ZA200706740B/xx unknown
- 2007-08-20 IL IL185391A patent/IL185391A0/en unknown
- 2007-10-08 NO NO20075074A patent/NO20075074L/no not_active Application Discontinuation
-
2010
- 2010-06-28 US US12/824,702 patent/US20100261741A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200706740B (en) | 2008-09-25 |
| CA2600868A1 (en) | 2006-09-21 |
| EP1858520B1 (de) | 2011-10-05 |
| IL185391A0 (en) | 2008-02-09 |
| NO20075074L (no) | 2007-11-30 |
| CN101137380A (zh) | 2008-03-05 |
| EP1858520A2 (de) | 2007-11-28 |
| AU2006223469A1 (en) | 2006-09-21 |
| US20100261741A1 (en) | 2010-10-14 |
| MX2007010965A (es) | 2007-09-19 |
| KR20070110081A (ko) | 2007-11-15 |
| WO2006098969A3 (en) | 2007-03-01 |
| US20080167329A1 (en) | 2008-07-10 |
| RU2007137266A (ru) | 2009-04-20 |
| US7745452B2 (en) | 2010-06-29 |
| WO2006098969A2 (en) | 2006-09-21 |
| JP2008533020A (ja) | 2008-08-21 |
| BRPI0608343A2 (pt) | 2016-10-04 |
| EP1858520A4 (de) | 2010-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075074L (no) | Kinazolinon T-type-kalsiumkanalantagonister | |
| MX2010004530A (es) | Antagonistas de los canales de calcio tipo t de heterociclo fenil amida. | |
| WO2007120729A3 (en) | Pyridyl amide t-type calcium channel antagonists | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| EA201690265A2 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| WO2007002884A3 (en) | 4-fluoro-piperidine t-type calcium channel antagonists | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| TW200714604A (en) | Substituted heterocycles and the uses thereof | |
| NO20082026L (no) | Deazapuriner som er nyttige som inhibitorer for Janus-kinaser | |
| DE602007008434D1 (de) | Rezeptoren | |
| MX2009010127A (es) | Compuestos utiles como inhibidores de janus cinasas. | |
| DE602004013563D1 (de) | Rantagonisten | |
| CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
| ECSP077421A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1 | |
| DE602006004844D1 (de) | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren | |
| DE602005027707D1 (de) | Isoindolin-verbindungen und deren verwendungen | |
| EA200700035A1 (ru) | Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders | |
| EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
| EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
| EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
| CL2007002578A1 (es) | Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer. | |
| ATE493412T1 (de) | Spirohydantoin-aryl-cgrp-rezeptorantagonisten | |
| CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
| CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
| WO2007002361A3 (en) | 3-fluoro-piperidine t-type calcium channel antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |